Bluejay Diagnostics, Inc. (BJDX): Submission of Matters to a Vote of Security Holders

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split ACTON, Mass., October 30, 2026 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient di

Event · Shareholder vote
Original reporting
Published Nov 4, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$BJDX
Neutral
high confidence
Mentioned
$BJDX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BJDXNeutralMed
01

Why it matters

The reverse split will adjust share count and may improve per‑share price perception, but does not change the company's cash position or product pipeline.

02

Market read

Primary corporate action for a micro‑cap; limited broader market impact but relevant for shareholders and short‑term traders.

03

What to watch

The split does not address the company's lack of FDA clearance for its Symphony™ system, which remains the primary risk.

Relevance 6/10Novelty 6/10Timing: effective Nov 3, 2026 – pre‑market adjustment expected

Background

Bluejay Diagnostics is a Nasdaq‑listed micro‑cap focused on near‑patient diagnostic platforms, currently awaiting FDA clearance for its lead product.

Company-level read

Ticker impact

$BJDXNeutralHigh confidence
Context

Bluejay Diagnostics announced a 1‑for‑4 reverse stock split effective Nov 3, 2026, reducing shares outstanding and adjusting warrants.

Expected impact

potential pressure as investors reassess valuation post‑split

Evidence & confidence

Reverse splits often trigger trading activity and can lead to temporary price swings, but no fundamental change to the business.

Market effects

Minimal; the diagnostic sector is not broadly impacted by a single micro‑cap split.

Limited to U.S. small‑cap investors and Nasdaq Capital Market participants.

Low; no global macro or sector ripple effects.

Counterpoint

Some traders may view the split as a chance to buy at a lower share price if they believe the business fundamentals remain intact.

Key entities

  • Bluejay Diagnostics, Inc.

    Medical diagnostics firm announcing the reverse split.

  • Continental Stock Transfer & Trust Company

    Acting as exchange agent for the split.

Related articles

$BJDXMed

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update Completes SYMON-II clinical study enrollment and advances clinical validation activities Achieves critical manufacturing milestone ahead of contractual deadline, strengtheni

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 For Immediate Release Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock. SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Towar

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics (NASDAQ:BJDX) announced baseline clinical data from its SYMON-II study, evaluating IL-6 as a biomarker for 28-day mortality risk in sepsis patients. The study included 777 patients, with an 18% mortality rate. The company aims to use this data to support a regulatory submission for its Symphony IL-6 Test, which is not yet FDA-approved.